Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Simpson Querrey Institute for Epigenetics, Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Mol Cell. 2022 Dec 15;82(24):4611-4626.e7. doi: 10.1016/j.molcel.2022.11.010. Epub 2022 Dec 6.
PALI1 is a newly identified accessory protein of the Polycomb repressive complex 2 (PRC2) that catalyzes H3K27 methylation. However, the roles of PALI1 in cancer are yet to be defined. Here, we report that PALI1 is upregulated in advanced prostate cancer (PCa) and competes with JARID2 for binding to the PRC2 core subunit SUZ12. PALI1 further interacts with the H3K9 methyltransferase G9A, bridging the formation of a unique G9A-PALI1-PRC2 super-complex that occupies a subset of G9A-target genes to mediate dual H3K9/K27 methylation and gene repression. Many of these genes are developmental regulators required for cell differentiation, and their loss in PCa predicts poor prognosis. Accordingly, PALI1 and G9A drive PCa cell proliferation and invasion in vitro and xenograft tumor growth in vivo. Collectively, our study shows that PALI1 harnesses two central epigenetic mechanisms to suppress cellular differentiation and promote tumorigenesis, which can be targeted by dual EZH2 and G9A inhibition.
PALI1 是多梳抑制复合物 2 (PRC2) 的一种新鉴定的辅助蛋白,能够催化 H3K27 甲基化。然而,PALI1 在癌症中的作用尚未确定。在这里,我们报告 PALI1 在晚期前列腺癌 (PCa) 中上调,并与 JARID2 竞争结合 PRC2 核心亚基 SUZ12。PALI1 进一步与 H3K9 甲基转移酶 G9A 相互作用,形成独特的 G9A-PALI1-PRC2 超复合物,占据 G9A 靶基因的一部分,介导双重 H3K9/K27 甲基化和基因抑制。这些基因中有许多是细胞分化所必需的发育调节剂,它们在 PCa 中的缺失预示着预后不良。因此,PALI1 和 G9A 在体外促进 PCa 细胞增殖和侵袭,并在体内促进异种移植肿瘤生长。总之,我们的研究表明,PALI1 利用两种核心表观遗传机制来抑制细胞分化并促进肿瘤发生,这可以通过双重 EZH2 和 G9A 抑制来靶向。